Search Results
Carboplatin
Carboplatin is FDA approved to treat people who have certain kinds of cancer, including some blood cancers. Carboplatin may cause temporary loss of hair during treatment. Normal hair growth should return after treatment ends.
Ask the Doctor Part 3: Five Questions about Myeloma
Myeloma Survivor, Sharon Clark Talks to Dr. Nichols about the Latest in Myeloma Research and Treatment
CAR-T Immunotherapy Showing Positive Results
This week, positive data from a Kite Pharma CAR-T immunotherapy clinical trial was released showing that more than one-third of refractory aggressive non-Hodgkin lymphoma (NHL) patients in the study showed no signs of the disease after six months.
Since 2015, The Leukemia & Lymphoma Society has been funding this study through its collaboration with Kite Pharma, a biotechnology company focused on immunotherapy.
Balancing fiscal responsibility with saving and improving lives
Table of contents:
How to start accepting help
It’s been another long day. A long list to check off. You’re doing it all yourself, making sure everything is in order, that everyone has what they need.
And you’re exhausted. But asking for help—or even accepting it when it’s offered—might seem intimidating. You don’t want to overwhelm others or bring them down.
Cancer might happen in the body, but its impact goes beyond that. Whether you’ve been diagnosed or someone you love has, if you feel stressed out or like you’re on your own, you’re not the only one.
LLS Partner Advances Promising Therapy for Rare Leukemia
A potential new therapeutic approach for blastic plasmacytoid dendritic cell neoplasm (BPDCN), a very rare form of blood cancer with no standard treatment, continues to show promise as it moves through early clinical trials. The Leukemia & Lymphoma Society (LLS) has a long history of supporting the development of SL-401, a targeted therapy that has shown significant anti-tumor effects.
Working with Lawmakers to Address the Unique Needs of Cancer Patients
As the coronavirus continues its spread, The Leukemia & Lymphoma Society (LLS) has a vital role to play in ensuring our government takes every step necessary to protect cancer patients. With that in mind, we’re sharing with our community what LLS has been doing to make sure the unique needs of blood cancer patients are being heard by the government at this unprecedented time.
BRIDGE (Blood cancer Research Initiative Developing Greater Engagement) with community patients
The Weill Cornell Medicine (WCM) Meyer Cancer Center (MCC) has an internationally recognized, clinical/translational blood cancer research program focused at its Manhattan campus. Elsewhere in New York City, the borough of Queens has 2.3 million and the borough of Brooklyn has 2.5 million residents. Both are among the most ethnically diverse urban areas in the world, and each separately ranks just behind Los Angeles and Chicago in population. Over 50% of patients diagnosed with blood cancers in New York City live in Brooklyn or Queens, and half of those are non-white.
Stopping Gleevec to Start a Family
Erin Zammett Ruddy is a magazine journalist and blogger who was diagnosed with chronic myeloid leukemia at age 23. Today, she is a 40-year-old mother of three.
On January 30 I turned 40. The big 4-0! My grandma Adele and I shared a birthday, and she’d be aghast if she knew I was telling all of you my real age right now. Grandma Del was a Radio City Rockette and very glamorous—and she never turned a day over 29, despite living to 85 (sorry, Grandma). But I am damn proud of being 40, newly-formed wrinkles and all.
Another Option Available for Multiple Myeloma Patients
Just on the heels of two approvals last week, the FDA today approved a third therapy to treat patients with multiple myeloma. Elotuzumab (Emplicity ™) is approved for use in combination with another drug, lenalidomide (Revlimid ®) for patients who have failed previous therapies.
#ASH18: The Beat Goes On
On Sunday, I reported on a press briefing at the 60th ASH Annual Meeting where the preliminary findings of our Beat AML Master Clinical Trial were unveiled. This innovative collaborative study is designed to bring the hope of precision medicine to patients with acute myeloid leukemia (AML). (Read about our Friday ASH satellite symposium on immunotherapy here).
A New CAR-T Approval Brings Hope for Mantle Cell Lymphoma Patients
The U.S. Food and Drug Administration (FDA) today announced its approval for a breakthrough treatment that will bring the promise of immunotherapy and new hope to thousands of patients diagnosed with mantle cell lymphoma (MCL) whose previous treatments fail to bring them lasting remissions.
Ifosfamide
Ifosfamide is an FDA-approved cancer therapy that is used to treat several types of cancer including acute lymphoblastic leukemia and non-Hodgkin lymphoma. It may cause temporary loss of hair in some people. After treatment has ended, normal hair growth should return.
Dispelling Misunderstandings About Clinical Trials
As a clinical trials specialist for The Leukemia & Lymphoma Society, I guide blood cancer patients and their families through the process of determining whether a clinical trial might be right for them. I try to clarify any misconceptions people have about what is involved so they will be in a much better place to make a decision. This blog addresses some of the most common misunderstandings. Considering a clinical trial for treatment of a blood cancer?
My Myeloma Story
“What is multiple myeloma?” Those were my words after the doctor’s review of my lab results for a routine and random high blood pressure exam in November 2008.
How Surviving Cancer Gave me a Second Birthday
Birthdays are a time for celebration as we become one year older, wiser, and more mature. For cancer survivors, we carry with us another date that symbolizes even more. This is our second birthday. Similar to an actual birthday, this day often carries feelings of even more nostalgia and remembrance. However, it can also grip us with feelings of dread, anxiety, and even post-traumatic stress disorder (PTSD). No matter how far along we are in our journey through survivorship, our second birthday pulls at us to stop and compassionately remember all that we’ve been through.
Understanding Myeloma: A Quick Guide
Myeloma is a rare blood cancer